AbbVie claims Phase 3 win for multiple myeloma drug etentamig
Phase 3positiveetentamigPositive
AI Analysis
Summary
AbbVie announced positive Phase 3 trial results for etentamig in multiple myeloma, demonstrating a 60% reduction in disease progression or death risk versus standard therapies. The company plans to advance the T cell engager program.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
60% reduction in risk of disease progression or death compared with standard therapies
Importance:8/10
Sentiment:
0.85
multiple myelomaT cell engagerPhase 3 dataoncology
Related Companies
Read the original article
Published by Endpoints News on September 3, 2026 2:50 PM